慢性骨髄性白血病治療の世界市場レポート 2025年

慢性骨髄性白血病治療市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR7.7％で131億2,000万米ドルに成長します。予測期間の成長は、効果的で忍容性の高い治療に対する需要の高まり、ヘルスケア支出の増加、慢性骨髄性白血病治療への投資、個別化医療の拡大などに起因すると考えられます。予測期間における主な動向には、診断とスクリーニングの改善、慢性骨髄性白血病の革新的治療、標的療法の開発、高度な早期診断とスクリーニング、モニタリング技術が含まれます。

骨髄性白血病の罹患率の上昇は、今後数年間における慢性骨髄性白血病（CML）治療市場の拡大を牽引するものと思われます。骨髄性白血病は骨髄に発生するがんの一種で、様々な種類の血液細胞を産生する細胞を侵します。慢性骨髄性白血病（CML）治療の主な目的は、白血病の根本原因に対処することで骨髄機能を強化し、最終的には血球数の低下に関連する合併症のリスクを低下させ、化学療法や移植の必要性を減らし、骨髄性白血病患者の生存率を改善することです。例えば、2023年1月、米国の任意団体である米国がん協会（American Cancer Society）は、2023年中に成人の急性骨髄性白血病（AML）による患者数は約20,380人、死亡者数は約11,310人と推定しています。その結果、骨髄性白血病の発生率の上昇が慢性骨髄性白血病（CML）治療市場の成長の原動力となっています。

染色体異常の罹患率の上昇は、今後数年間における慢性骨髄性白血病（CML）治療市場拡大の主要な促進要因になると予想されます。染色体異常は、遺伝情報の重要な担い手である個人の染色体における構造的または数値的な異常を包含しており、患者の予後に重大な影響を及ぼし、特にCMLの場合、より積極的な治療が必要となる可能性があります。例えば、サウジアラビアで実施された調査によると、先天異常のある新生児59人のうち39.3％に染色体異常が認められ、新生児集中治療室（NICU）入室者全体の2.3％を占めていたことが、米国を拠点とする生物医学情報学と計算健康データ科学研究の専門機関である国立医学図書館（NLM）の報告から明らかになりました。その結果、染色体異常の有病率の増加が慢性骨髄性白血病（CML）治療市場の拡大を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界慢性骨髄性白血病治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の慢性骨髄性白血病治療市場：成長率分析
• 世界の慢性骨髄性白血病治療市場の実績：規模と成長, 2019-2024
• 世界の慢性骨髄性白血病治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界慢性骨髄性白血病治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の慢性骨髄性白血病治療市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 標的療法
• 化学療法
• 放射線治療
• 脾臓摘出術
• 幹細胞移植
• 世界の慢性骨髄性白血病治療市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 非経口
• その他の投与経路
• 世界の慢性骨髄性白血病治療市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• その他のエンドユーザー
• 世界の慢性骨髄性白血病治療市場、標的療法のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• チロシンキナーゼ阻害剤（TKI）
• モノクローナル抗体
• 世界の慢性骨髄性白血病治療市場化学療法の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• 併用化学療法
• 単剤化学療法
• 世界の慢性骨髄性白血病治療市場、放射線治療の種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 外部放射線治療
• 全身照射
• 世界の慢性骨髄性白血病治療市場脾臓摘出術のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 開腹脾臓摘出術
• 腹腔鏡下脾臓摘出術
• 世界の慢性骨髄性白血病治療市場幹細胞移植の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
• 自家幹細胞移植
• 同種幹細胞移植

第7章 地域別・国別分析

• 世界の慢性骨髄性白血病治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の慢性骨髄性白血病治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 慢性骨髄性白血病治療市場：競合情勢
• 慢性骨髄性白血病治療市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson and Johnson Limited Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Merck and Co. Inc.
• Sanofi S.A.
• Bristol-Myers Squibb Company
• AstraZeneca Plc
• GSK Plc
• Takeda Pharmaceutical Company Limited
• Amgen Inc.
• Boehringer Ingelheim International GmbH
• Teva Pharmaceutical Industries Ltd.
• Astellas Pharma Inc
• Otsuka Holdings Co Ltd.
• Mylan N.V.
• Astellas Pharma Inc.
• Incyte Corporation
• Lupin Limited

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 慢性骨髄性白血病治療市場2029：新たな機会を提供する国
• 慢性骨髄性白血病治療市場2029：新たな機会を提供するセグメント
• 慢性骨髄性白血病治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Chronic myeloid leukemia (CML) constitutes a form of cancer that exerts its impact on the bone marrow and blood cells. It is characterized by the excessive production of abnormal white blood cells, referred to as granulocytes. The core objective of CML treatment is the management of the disease, alleviation of symptoms, and enhancement of the overall quality of life for patients grappling with this condition.

Treatment options in the domain of chronic myeloid leukemia encompass a range of approaches, including targeted therapy, chemotherapy, radiation therapy, splenectomy, and stem cell transplantation. Among these, targeted therapy assumes prominence as a cancer treatment modality focused on specific molecules or pathways integral to the growth and survival of cancer cells. The administration of these treatments can occur through diverse routes, including oral and parenteral methods, and caters to various end-users such as hospitals and specialized clinics, ultimately underscoring the comprehensive nature of CML management.

The chronic myeloid leukemia treatment market research report is one of a series of new reports from The Business Research Company that provides chronic myeloid leukemia treatment market statistics, including chronic myeloid leukemia treatment industry global market size, regional shares, competitors with a chronic myeloid leukemia treatment market share, detailed chronic myeloid leukemia treatment market segments, market trends and opportunities and any further data you may need to thrive in the chronic myeloid leukemia treatment industry. This chronic myeloid leukemia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The chronic myeloid leukemia treatment market size has grown strongly in recent years. It will grow from $9.2 billion in 2024 to $9.76 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to rising prevalence of chronic myeloid leukemia, growing awareness about cancer treatment, government initiatives, growing research and development activities for chronic myeloid leukemia treatments.

The chronic myeloid leukemia treatment market size is expected to see strong growth in the next few years. It will grow to $13.12 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to growing demand for effective and more tolerable treatments, rising healthcare spending, investments in chronic myeloid leukemia treatments, growing personalized medicine. Major trends in the forecast period include improved diagnosis and screening, innovative treatments for chronic myeloid leukemia, development of targeted therapies, advanced early diagnosis and screening, monitoring technologies.

The rising incidence of myeloid leukemia is poised to drive the expansion of the chronic myeloid leukemia (CML) treatment market in the coming years. Myeloid leukemia, a form of cancer originating in the bone marrow, affects the cells responsible for producing various blood cell types. The primary objective of chronic myeloid leukemia (CML) treatment is to enhance bone marrow function by addressing the root cause of leukemia, ultimately lowering the risk of complications related to low blood cell counts, reducing the necessity for chemotherapy and transplants, and improving survival rates among individuals with myeloid leukemia. For instance, in January 2023, the American Cancer Society, a US-based voluntary health organization, estimated that there were approximately 20,380 cases and 11,310 deaths from acute myeloid leukemia (AML) in adults during the year 2023. Consequently, the escalating incidence of myeloid leukemia serves as a driving force behind the chronic myeloid leukemia (CML) treatment market's growth.

The rising incidence of chromosome abnormalities is expected to be a key driver behind the expansion of the chronic myeloid leukemia (CML) treatment market in the coming years. Chromosome abnormalities, which encompass structural or numerical irregularities in an individual's chromosomes-critical carriers of genetic information, have a significant impact on patients' prognoses and may necessitate more aggressive treatments, particularly in cases of CML. For instance, based on a study conducted in Saudi Arabia, it was revealed that chromosome abnormalities were present in 39.3% of 59 newborn infants with congenital anomalies, accounting for 2.3% of total neonatal intensive care unit (NICU) admissions, as reported by the National Library of Medicine (NLM), a US-based institution specializing in biomedical informatics and computational health data science research. Consequently, the increasing prevalence of chromosome abnormalities is driving the expansion of the chronic myeloid leukemia (CML) treatment market.

Prominent companies in the chronic myeloid leukemia (CML) treatment market prioritize the development of groundbreaking diagnostic products to maintain their market presence. An illustrative instance of such innovation is found in the actions of Precipio, Inc., a US-based diagnostic company specializing in cancer diagnostics. For instance, in August 2023, Precipio, Inc. introduced the BCR-ABL 2.0 Panel, specifically designed for chronic myeloid leukemia (CML) diagnosis. This advanced panel plays a pivotal role in identifying the BCR-ABL1 gene, which is crucial for diagnosing CML. It stands out as the most sophisticated BCR-ABL panel, distinguished by its comprehensive coverage, streamlined workflow, reduced costs, and the enhanced quality of patient care. Notably, it includes the detection of ABL1 mutations, eliminating the necessity for a secondary round of testing for the BCR-ABL1 gene and providing highly accurate results. This remarkable innovation significantly shapes the landscape of chronic myeloid leukemia (CML) treatment.

In November 2022, Merck & Co. Inc., a US-based multinational pharmaceutical company, acquired Imago BioSciences for $1.35 billion. This acquisition enhances Merck's ability to develop cutting-edge therapies for hematologic malignancies, positioning the company to address unmet medical needs in cancer treatment, foster growth in a competitive market, and improve patient care. Imago BioSciences Inc., a US-based clinical-stage biopharmaceutical company, specializes in developing innovative treatments for myeloproliferative neoplasms and other bone marrow diseases, including chronic myelogenous leukemia, polycythemia vera, and essential thrombocythemia.

Major companies operating in the chronic myeloid leukemia treatment market are Pfizer Inc., Johnson and Johnson Limited, F. Hoffmann-La Roche AG, AbbVie Inc., Novartis AG, Merck and Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Takeda Pharmaceutical Company Limited, Amgen Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Otsuka Holdings Co Ltd., Mylan N.V., Astellas Pharma Inc., Incyte Corporation, Lupin Limited, Seattle Genetics Inc., Innovent Biologics Inc., Xencor Inc., ARIAD Pharmaceuticals Inc., Celon Laboratories Pvt. Ltd.

North America was the largest region in the chronic myeloid leukemia treatment market in 2024. The regions covered in chronic myeloid leukemia treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the chronic myeloid leukemia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chronic myeloid leukemia treatment market consists of revenues earned by entities by providing diagnosis and staging, medical consultations and follow-up care. The market value includes the value of related goods sold by the service provider or included within the service offering. The chronic myeloid leukemia (CML) market also includes sales of imatinib, dasatinib, bosutinib and ponatinib. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Chronic Myeloid Leukemia Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on chronic myeloid leukemia treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for chronic myeloid leukemia treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The chronic myeloid leukemia treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Targeted Therapy; Chemotherapy; Radiation Therapy; Splenectomy; Stem Cell Transplant
• 2) By Route of Administration: Oral; Parenteral; Other Route of Administrations
• 3) By End-User: Hospitals; Specialty Clinics; Other End-Users
• Subsegments:
• 1) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs); Monoclonal Antibodies
• 2) By Chemotherapy: Combination Chemotherapy; Single-Agent Chemotherapy
• 3) By Radiation Therapy: External Beam Radiation Therapy; Total Body Irradiation
• 4) By Splenectomy: Open Splenectomy; Laparoscopic Splenectomy
• 5) By Stem Cell Transplant: Autologous Stem Cell Transplant; Allogeneic Stem Cell Transplant
• Companies Mentioned: Pfizer Inc.; Johnson and Johnson Limited; F. Hoffmann-La Roche AG; AbbVie Inc.; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Chronic Myeloid Leukemia Treatment Market Characteristics

3. Chronic Myeloid Leukemia Treatment Market Trends And Strategies

4. Chronic Myeloid Leukemia Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Chronic Myeloid Leukemia Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Chronic Myeloid Leukemia Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Chronic Myeloid Leukemia Treatment Market Growth Rate Analysis
• 5.4. Global Chronic Myeloid Leukemia Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Chronic Myeloid Leukemia Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Chronic Myeloid Leukemia Treatment Total Addressable Market (TAM)

6. Chronic Myeloid Leukemia Treatment Market Segmentation

• 6.1. Global Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Targeted Therapy
• Chemotherapy
• Radiation Therapy
• Splenectomy
• Stem Cell Transplant
• 6.2. Global Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Route of Administrations
• 6.3. Global Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Other End-Users
• 6.4. Global Chronic Myeloid Leukemia Treatment Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tyrosine Kinase Inhibitors (TKIs)
• Monoclonal Antibodies
• 6.5. Global Chronic Myeloid Leukemia Treatment Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Combination Chemotherapy
• Single-Agent Chemotherapy
• 6.6. Global Chronic Myeloid Leukemia Treatment Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• External Beam Radiation Therapy
• Total Body Irradiation
• 6.7. Global Chronic Myeloid Leukemia Treatment Market, Sub-Segmentation Of Splenectomy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Open Splenectomy
• Laparoscopic Splenectomy
• 6.8. Global Chronic Myeloid Leukemia Treatment Market, Sub-Segmentation Of Stem Cell Transplant, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Autologous Stem Cell Transplant
• Allogeneic Stem Cell Transplant

7. Chronic Myeloid Leukemia Treatment Market Regional And Country Analysis

• 7.1. Global Chronic Myeloid Leukemia Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Chronic Myeloid Leukemia Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Chronic Myeloid Leukemia Treatment Market

• 8.1. Asia-Pacific Chronic Myeloid Leukemia Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Chronic Myeloid Leukemia Treatment Market

• 9.1. China Chronic Myeloid Leukemia Treatment Market Overview
• 9.2. China Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Chronic Myeloid Leukemia Treatment Market

• 10.1. India Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Chronic Myeloid Leukemia Treatment Market

• 11.1. Japan Chronic Myeloid Leukemia Treatment Market Overview
• 11.2. Japan Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Chronic Myeloid Leukemia Treatment Market

• 12.1. Australia Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Chronic Myeloid Leukemia Treatment Market

• 13.1. Indonesia Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Chronic Myeloid Leukemia Treatment Market

• 14.1. South Korea Chronic Myeloid Leukemia Treatment Market Overview
• 14.2. South Korea Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Chronic Myeloid Leukemia Treatment Market

• 15.1. Western Europe Chronic Myeloid Leukemia Treatment Market Overview
• 15.2. Western Europe Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Chronic Myeloid Leukemia Treatment Market

• 16.1. UK Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Chronic Myeloid Leukemia Treatment Market

• 17.1. Germany Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Chronic Myeloid Leukemia Treatment Market

• 18.1. France Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Chronic Myeloid Leukemia Treatment Market

• 19.1. Italy Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Chronic Myeloid Leukemia Treatment Market

• 20.1. Spain Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Chronic Myeloid Leukemia Treatment Market

• 21.1. Eastern Europe Chronic Myeloid Leukemia Treatment Market Overview
• 21.2. Eastern Europe Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Chronic Myeloid Leukemia Treatment Market

• 22.1. Russia Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Chronic Myeloid Leukemia Treatment Market

• 23.1. North America Chronic Myeloid Leukemia Treatment Market Overview
• 23.2. North America Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Chronic Myeloid Leukemia Treatment Market

• 24.1. USA Chronic Myeloid Leukemia Treatment Market Overview
• 24.2. USA Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Chronic Myeloid Leukemia Treatment Market

• 25.1. Canada Chronic Myeloid Leukemia Treatment Market Overview
• 25.2. Canada Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Chronic Myeloid Leukemia Treatment Market

• 26.1. South America Chronic Myeloid Leukemia Treatment Market Overview
• 26.2. South America Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Chronic Myeloid Leukemia Treatment Market

• 27.1. Brazil Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Chronic Myeloid Leukemia Treatment Market

• 28.1. Middle East Chronic Myeloid Leukemia Treatment Market Overview
• 28.2. Middle East Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Chronic Myeloid Leukemia Treatment Market

• 29.1. Africa Chronic Myeloid Leukemia Treatment Market Overview
• 29.2. Africa Chronic Myeloid Leukemia Treatment Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Chronic Myeloid Leukemia Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Chronic Myeloid Leukemia Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Chronic Myeloid Leukemia Treatment Market Competitive Landscape And Company Profiles

• 30.1. Chronic Myeloid Leukemia Treatment Market Competitive Landscape
• 30.2. Chronic Myeloid Leukemia Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson and Johnson Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Chronic Myeloid Leukemia Treatment Market Other Major And Innovative Companies

• 31.1. Merck and Co. Inc.
• 31.2. Sanofi S.A.
• 31.3. Bristol-Myers Squibb Company
• 31.4. AstraZeneca Plc
• 31.5. GSK Plc
• 31.6. Takeda Pharmaceutical Company Limited
• 31.7. Amgen Inc.
• 31.8. Boehringer Ingelheim International GmbH
• 31.9. Teva Pharmaceutical Industries Ltd.
• 31.10. Astellas Pharma Inc
• 31.11. Otsuka Holdings Co Ltd.
• 31.12. Mylan N.V.
• 31.13. Astellas Pharma Inc.
• 31.14. Incyte Corporation
• 31.15. Lupin Limited

32. Global Chronic Myeloid Leukemia Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Chronic Myeloid Leukemia Treatment Market

34. Recent Developments In The Chronic Myeloid Leukemia Treatment Market

35. Chronic Myeloid Leukemia Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Chronic Myeloid Leukemia Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Chronic Myeloid Leukemia Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Chronic Myeloid Leukemia Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer